ANTIGEN EXCLUSIVITY Sample Clauses

ANTIGEN EXCLUSIVITY. Subject to Sections 3.3.2 and 3.3.4, the Parties acknowledge and agree that this Collaboration shall be exclusive with respect to the Collaboration Targets and that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based products with respect to any Collaboration Target other than the Collaboration Products and Unilateral Products as provided in this Agreement and any related agreements between the Parties.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
ANTIGEN EXCLUSIVITY. Subject to Sections 2.2.2 and 2.2.4, the Parties acknowledge and agree that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based products with respect to any Unilateral Target listed on Appendix A other than the Unilateral Products as provided in this Agreement.
Sample 1
ANTIGEN EXCLUSIVITY. (a) Subject to Sections 3.3.2, 3.3.3 and 3.3.4, the Parties acknowledge and agree that this Collaboration shall be exclusive with respect to the Collaboration Targets and that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based prophylactic or therapeutic products with respect to any Collaboration Target other than the Collaboration Products and Unilateral Products as provided in this Agreement and any related agreements among the Parties. deCODE represents that it has entered into that certain Term Sheet re: Diagnostic Products between deCODE, a certain Third Party and Affiliates of such Third Party dated as of March 1, 2001, and any further agreement between deCODE, such Third Party and/or such Affiliates entered into pursuant thereto (the "PRE-EXISTING DIAGNOSTIC AGREEMENT"). deCODE acknowledges and agrees that it has no right to use, outside of the Collaboration, any Antibodies generated pursuant to this Agreement or a Unilateral Development and Commercialization Agreement, except as expressly set forth in the applicable Unilateral Development and Commercialization Agreement. (b) deCODE shall use commercially reasonable efforts (i) to develop and commercialize or cause to be developed and commercialized Diagnostic Products with respect to each Collaboration Target to the extent necessary or reasonably useful for the Exploitation of Collaboration Products with respect to such Collaboration Target, (ii) provide or cause to be provided such Diagnostic Products to the Collaborators at a commercially reasonable cost for use in connection with the development of such Collaboration Products, including to assist the Collaboration in selecting patients for clinical trials involving such Collaboration Products, and (iii) use commercially reasonable efforts, consistent with the Pre-Existing Diagnostic Agreement, to make such Diagnostic Products generally available to the public on commercially reasonable terms or cause to be so made to the extent necessary or reasonably useful to Exploit such Collaboration Products. (c) Notwithstanding clause (b) above, if at any time deCODE obtains rights, pursuant to the Pre-Existing Diagnostic Agreement or otherwise, to a Diagnostic Product with respect to a Collaboration Target, then deCODE shall offer such Diagnostic Product to Genmab/Medarex to be Exploited under the Collaboration as a Collaboration Pro...
Sample 1
ANTIGEN EXCLUSIVITY. (a) Subject to Sections 2.2.2, 2.2.3 and 2.2.4, the Parties acknowledge and agree that no Party shall engage, directly or indirectly, on behalf of itself or any other party, in the research, development, commercialization or other Exploitation of antibody-based prophylactic or therapeutic products with respect to any Unilateral Target listed on Appendix A other than the Unilateral Products as provided in this Agreement. deCODE represents that it has entered into that certain Term Sheet re: Diagnostic Products between deCODE, a certain Third Party and Affiliates of such Third Party dated as of March 1, 2001, and any further agreement between deCODE, such Third Party and/or such Affiliates entered into pursuant thereto (the "PRE-EXISTING DIAGNOSTIC AGREEMENT"). deCODE acknowledges and agrees that it has no right to use any Antibodies generated pursuant this Agreement or the Collaboration Agreement except as expressly set forth herein or therein. (b) deCODE shall use commercially reasonable efforts to (i) develop and commercialize or cause to be developed and commercialized Diagnostic Products with respect to each Unilateral Target to the extent necessary or reasonably useful for the Exploitation of Unilateral Products with respect to such Unilateral Target, and (ii) consistent with the Pre-Existing Diagnostic Agreement, make such Diagnostic Products generally available to the public on commercially reasonable terms or cause to be so made to the extent necessary or reasonably useful to Exploit such Unilateral Products.
Sample 1
ANTIGEN EXCLUSIVITY. Subject to Sections 3.3.2, 3.3.3 and 3.3.4, the Parties acknowledge and agree that no Party shall engage, directly or indirectly, on behalf of itself or with or through any other party, in the research, development, commercialization or other Exploitation of Antibody-Based Products with respect to the Collaboration Target, or grant any other right or license to do so, other than with respect to the Collaboration Products and Unilateral Products as provided in this Agreement and any related agreements between the Parties.
Sample 1

Related to ANTIGEN EXCLUSIVITY

  • Non-Exclusivity The services of the Adviser to the Manager, the Allocated Portion and the Trust are not to be deemed to be exclusive, and the Adviser shall be free to render investment advisory or other services to others and to engage in other activities. It is understood and agreed that the directors, officers, and employees of the Adviser are not prohibited from engaging in any other business activity or from rendering services to any other person, or from serving as partners, officers, directors, trustees, or employees of any other firm or corporation.

  • Non-exclusivity, Etc The rights of Indemnitee hereunder will be in addition to any other rights Indemnitee may have under the Charter, the Bylaws or the Maryland General Corporation Law (the "MGCL") or otherwise; provided, however, that to the extent that Indemnitee otherwise would have any greater right to indemnification under any provision of the Charter or Bylaws as in effect on the date hereof, Indemnitee will be deemed to have such greater right hereunder, and provided, further, that to the extent that any change is made to the MGCL (whether by legislative action or judicial decision), the Charter and/or the Bylaws which permits any greater right to indemnification than that provided under this Agreement as of the date hereof, Indemnitee will be deemed to have such greater right hereunder. The Company will not adopt any amendment to the Charter or the Bylaws the effect of which would be to deny, diminish or encumber Indenmitee's right to indemnification under the Charter, the Bylaws, the MGCL or otherwise as applied to any act or failure to act occurring in whole or in part prior to the date upon which the amendment was approved by the Company's Board of Directors and/or its stockholders, as the case may be.

  • No Exclusivity The remedies provided for in this Section 2.09 are not exclusive and shall not limit any rights or remedies which may be available to any indemnified party at law or in equity or pursuant to any other agreement.

  • Non-Exclusive License Sponsor grants Institution and Principal Investigator a royalty free non-exclusive license, with no right to sublicense, to use Trial Data for internal research or educational purposes.

  • Exclusivity Without prejudice to the Company’s rights under Section 5.4, the Company agrees not to appoint any other depositary for issuance of depositary shares, depositary receipts or any similar securities or instruments so long as The Bank of New York Mellon is acting as Depositary under this Deposit Agreement.

  • Non-exclusivity of Rights Nothing in this Agreement shall prevent or limit the Executive's continuing or future participation in any plan, program, policy or practice provided by the Company or any of its affiliated companies and for which the Executive may qualify, nor, subject to Section 12(f), shall anything herein limit or otherwise affect such rights as the Executive may have under any contract or agreement with the Company or any of its affiliated companies. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.

  • Limited Exclusivity The Sub-Advisor agrees that it will not provide similar services to any other mutual fund which holds itself out to the public as “Environmentally Qualified” or otherwise “Socially Responsible” within the common meanings of those terms. Other than that, it is understood that the services of the Sub-Advisor are not exclusive, and that nothing in this Agreement shall prevent the Sub-Advisor from providing similar services to other investment advisory clients, including but not by way of limitation, investment companies or to other series of investment companies, including the Trust (whether or not their investment objectives and policies are similar to those of the Fund) or from engaging in other activities, provided such other services and activities do not, during the term of this Agreement, interfere in a material manner with the Sub-Advisor’s ability to meet its obligations to the Fund hereunder. When the Sub-Advisor recommends the purchase or sale of a security for other investment companies and other clients, and at the same time the Sub-Advisor recommends the purchase or sale of the same security for the Fund, it is understood that in light of its fiduciary duty to the Fund, such transactions will be executed on a basis that is fair and equitable to the Fund. If the Sub-Advisor provides any advice to its clients concerning the shares of the Fund, the Sub-Advisor shall act solely as investment counsel for such clients and not in any way on behalf of the Trust or the Fund. The Sub-Advisor provides investment advisory services to numerous other investment advisory clients, including but not limited to other funds and may give advice and take action which may differ from the timing or nature of action taken by the Sub-Advisor with respect to the Fund. Nothing in this Agreement shall impose upon the Sub-Advisor any obligations other than those imposed by law to purchase, sell or recommend for purchase or sale, with respect to the Fund, any security which the Sub-Advisor, or the shareholders, officers, directors, employees or affiliates may purchase or sell for their own account or for the account of any client.

  • Non-Exclusivity; Survival of Rights; Subrogation (a) The rights of indemnification and advance of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the charter or Bylaws of the Company, any agreement or a resolution of the stockholders entitled to vote generally in the election of directors or of the Board of Directors, or otherwise. Unless consented to in writing by Indemnitee, no amendment, alteration or repeal of the charter or Bylaws of the Company, this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in Indemnitee’s Corporate Status prior to such amendment, alteration or repeal, regardless of whether a claim with respect to such action or inaction is raised prior or subsequent to such amendment, alteration or repeal. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right or remedy shall be cumulative and in addition to every other right or remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion of any right or remedy hereunder, or otherwise, shall not prohibit the concurrent assertion or employment of any other right or remedy. (b) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

  • Non-Exclusive Services The services of the Adviser to the Trust are not deemed exclusive, and the Adviser shall be free to render similar services to others, to the extent that such service does not affect the Adviser’s ability to perform its duties and obligations hereunder.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!